• Edouard Ollier, Fabrice Heritier, Caroline Bonnet, Sophie Hodin, Brigitte Beauchesne, Serge Molliex, and Xavier Delavenne.
• Université Claude Bernard Lyon 1, F-69100, Villeurbanne, France.
• Br J Clin Pharmacol. 2015 Jul 1; 80 (1): 67-74.

AimsThe aim of this study was to develop a pharmacokinetic model in order to characterize the free and total ropivacaine concentrations after transversus abdominis plane block in a population of patients undergoing liver resection surgery. In particular, we evaluated the impact of the size of liver resection on ropivacaine pharmacokinetics.MethodsThis work is based on a single-centre, double-blinded, randomized, placebo-controlled study. Among the 39 patients included, 19 patients were randomized to the ropivacaine group. The free and total ropivacaine concentrations were measured in nine or 10 blood samples per patient. A pharmacokinetic model was built using a nonlinear mixed-effect modelling approach.ResultsThe free ropivacaine concentrations remained under the previously published toxic threshold. A one-compartment model, including protein binding site with a first-order absorption, best described the data. The protein binding site concentration was considered as a latent variable. Bodyweight, the number of resected liver segments and postoperative fibrinogen evolution were, respectively, included in the calculation of the volume of distribution, clearance and binding site production rate. The resection of three or more liver segments was associated with a 53% decrease in the free ropivacaine clearance.ConclusionsAlthough large liver resections were associated with lower free ropivacaine clearance, the ropivacaine pharmacokinetic profile remained within the safe range after this type of surgery.© 2014 The British Pharmacological Society.

24 keywords...

hide…